Anne Barlier Selected Research

Everolimus

9/2022	Co-Targeting MAP Kinase and Pi3K-Akt-mTOR Pathways in Meningioma: Preclinical Study of Alpelisib and Trametinib.
1/2021	Role of 3D volume growth rate for drug activity evaluation in meningioma clinical trials: the example of the CEVOREM study.
1/2020	Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial.
8/2017	Pasireotide is more effective than octreotide, alone or combined with everolimus on human meningioma in vitro.
6/2017	Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?
8/2015	Combined treatment by octreotide and everolimus: Octreotide enhances inhibitory effect of everolimus in aggressive meningiomas.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Anne Barlier Research Topics

Disease

40	Neoplasms (Cancer) 04/2024 - 05/2007
17	Pituitary Neoplasms (Pituitary Adenoma) 12/2023 - 10/2004
10	Paraganglioma (Paragangliomas) 05/2020 - 05/2009
9	Meningioma (Meningiomas) 04/2024 - 08/2015
8	Neuroendocrine Tumors (Neuroendocrine Tumor) 01/2022 - 04/2014
8	Pheochromocytoma 05/2018 - 05/2009
7	Hypopituitarism (Sheehan's Syndrome) 12/2023 - 03/2004
7	Prolactinoma (Prolactinomas) 01/2023 - 05/2007
6	Adenoma (Adenomas) 11/2022 - 10/2004
6	Growth Hormone-Secreting Pituitary Adenoma 06/2021 - 10/2004
5	Acromegaly 12/2023 - 12/2014
4	Neoplasm Metastasis (Metastasis) 01/2022 - 06/2012
3	Carcinogenesis 09/2022 - 05/2007
3	Primitive Neuroectodermal Tumors (PNET) 02/2020 - 10/2014
3	Combined Pituitary Hormone Deficiency 01/2019 - 09/2006
2	Common Variable Immunodeficiency 01/2023 - 01/2012
2	Hypoglycemia (Reactive Hypoglycemia) 01/2023 - 01/2012
2	Hypothyroidism 01/2023 - 01/2015
2	Hypoxia (Hypoxemia) 01/2020 - 02/2016
2	Polyostotic Fibrous Dysplasia (McCune Albright Syndrome) 01/2019 - 10/2014
2	Polycythemia (Erythrocytosis) 05/2018 - 05/2013
2	Hyperplasia 12/2017 - 03/2016
2	Pseudohypoparathyroidism 12/2016 - 04/2015
2	Gigantism 03/2016 - 12/2014
2	Infections 01/2012 - 12/2008
1	Ependymoma 04/2024
1	Thyroid Nodule (Nodule, Thyroid) 12/2023
1	Fatigue 12/2023
1	Colonic Polyps 12/2023
1	Glioblastoma (Glioblastoma Multiforme) 12/2023
1	Arthralgia (Joint Pain) 12/2023
1	Vision Disorders (Hemeralopia) 12/2023
1	Headache (Headaches) 12/2023
1	Carpal Tunnel Syndrome 12/2023
1	Erectile Dysfunction 12/2023
1	COVID-19 01/2023
1	Agammaglobulinemia (Hypogammaglobulinemia) 01/2023
1	Primary Hyperparathyroidism 01/2022
1	Cognitive Dysfunction 01/2022
1	Endocrine System Diseases (Endocrine Diseases) 01/2020
1	Hypertension (High Blood Pressure) 05/2018
1	Hemangioblastoma 05/2018

Drug/Important Bio-Agent (IBA)

16	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 11/2022 - 05/2008
13	Octreotide (Sandostatin)FDA LinkGeneric 11/2022 - 09/2007
11	ProlactinIBA 12/2023 - 12/2006
9	Somatostatin Receptors (Somatostatin Receptor)IBA 11/2022 - 12/2008
7	Hormones (Hormone)IBA 12/2023 - 03/2004
7	Adrenocorticotropic Hormone (ACTH)FDA Link 01/2023 - 03/2005
7	Transcription Factors (Transcription Factor)IBA 01/2019 - 03/2004
7	Proteins (Proteins, Gene)FDA Link 12/2017 - 05/2007
6	Growth Hormone (Somatotropin)IBA 01/2023 - 12/2008
6	Dopamine Agonists (Dopamine Agonist)IBA 01/2023 - 02/2006
6	Everolimus FDA Link 09/2022 - 08/2015
6	Dopamine (Intropin)FDA LinkGeneric 06/2021 - 05/2008
6	Succinate Dehydrogenase (Fumarate Reductase)IBA 05/2020 - 05/2009
6	Messenger RNA (mRNA)IBA 09/2017 - 09/2007
5	aryl hydrocarbon receptor-interacting proteinIBA 01/2023 - 05/2007
5	Cabergoline FDA LinkGeneric 01/2023 - 02/2006
5	pasireotideIBA 11/2022 - 05/2008
5	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 08/2017 - 05/2009
4	DNA (Deoxyribonucleic Acid)IBA 04/2024 - 04/2015
2	Immunoglobulins (Immunoglobulin)IBA 01/2023 - 06/2016
2	Hydrocortisone (Cortisol)FDA LinkGeneric 01/2023 - 12/2011
2	LigandsIBA 11/2022 - 05/2008
2	Insulin-Like Growth Factor I (IGF-1)IBA 11/2022 - 11/2010
2	Cell-Free Nucleic AcidsIBA 01/2022 - 01/2019
2	fluorodopa F 18IBA 02/2020 - 12/2017
2	Human Growth Hormone (Saizen)FDA LinkGeneric 01/2020 - 10/2004
2	Adenosine Monophosphate (AMP)IBA 01/2019 - 01/2013
2	Temozolomide (Temodar)FDA LinkGeneric 01/2019 - 06/2012
2	NormetanephrineIBA 05/2018 - 03/2017
2	Parathyroid Hormone (Parathormone)IBA 12/2016 - 04/2015
2	Glycoproteins (Glycoprotein)IBA 06/2016 - 10/2004
2	Succinic Acid (Succinate)IBA 01/2015 - 01/2013
2	Glutamic Acid (Glutamate)FDA Link 01/2015 - 01/2013
2	Dopamine Receptors (Dopamine Receptor)IBA 12/2013 - 04/2011
2	Norepinephrine (Noradrenaline)FDA LinkGeneric 05/2013 - 04/2011
2	TBR-760IBA 05/2012 - 05/2008
2	GlucocorticoidsIBA 12/2011 - 03/2005
1	Immunoglobulin M (IgM)IBA 01/2023
1	Thyrotropin (Thyroid-Stimulating Hormone)FDA Link 01/2023
1	Immunoglobulin A (IgA)IBA 01/2023
1	Phosphotransferases (Kinase)IBA 09/2022
1	trametinibIBA 09/2022
1	AlpelisibIBA 09/2022
1	Isolated ACTH DeficiencyIBA 01/2022
1	Tumor Biomarkers (Tumor Markers)IBA 01/2022
1	Circulating Tumor DNAIBA 01/2022
1	Complement System Proteins (Complement)IBA 01/2021
1	Protein Isoforms (Isoforms)IBA 01/2021
1	gallium Ga 68 dotatateIBA 02/2020
1	Cyclic AMP-Dependent Protein Kinases (cAMP-Dependent Protein Kinase)IBA 01/2020
1	somatostatin receptor 2IBA 01/2020
1	FluorineIBA 05/2018
1	Glucose (Dextrose)FDA LinkGeneric 05/2018

Therapy/Procedure

17	Therapeutics 06/2021 - 10/2004
4	Radiotherapy 01/2020 - 11/2010
3	Drug Therapy (Chemotherapy) 12/2023 - 06/2012
1	Proton Therapy 01/2020
1	Aftercare (After-Treatment) 01/2020